Randomized Trial: Shortening Adjuvant Trastuzumab to 6 Months in Selected Patients with Breast Cancer

ASCO 2018: Shortening Adjuvant Trastuzumab to 6 Months in Patients With HER2-Positive Early Breast Cancer Is Effective and Reduces Cardiac Toxicities – The ASCO Post (free)

Commentaries: Test of Herceptin Finds Briefer Treatment Can Work, With Fewer Side Effects – NPR (free) AND Shorter drug treatment OK for many breast cancer patients – Associated Press (free) AND For Women With Early Breast Cancer, Herceptin Treatment Can Be Much Shorter – The New York Times (10 articles per month are free)

““For women with early-stage breast cancer who needed the drug Herceptin, 6 months of treatment were as good as 12, a major study found. Less risk of side effects, less cost, less time “being a patient.”” (via @NYTHealth see Tweet)